Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Exploring Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Extinction Learning-Based Treatment Outcome in Obsessive-Compulsive Disorder: A Pilot Study.

Literature DB >> 30531475

Exploring Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Extinction Learning-Based Treatment Outcome in Obsessive-Compulsive Disorder: A Pilot Study.

Omer Linkovski¹, Michael G Wheaton, Jordana Zwerling, Zagaa Odgerel, Peter van Roessel, Maria Filippou-Frye, Anthony Lombardi, Brianna Wright, Shari A Steinman, Helen Blair Simpson, Francis Lee, Carolyn I Rodriguez.

Abstract

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2019 PMID： 30531475 PMCID： PMC7326118 DOI： 10.1097/JCP.0000000000000994

Source DB: PubMed Journal: J Clin Psychopharmacol ISSN： 0271-0749 Impact factor: 3.153

× No keyword cloud information.

11 in total

1. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex.

Authors: Rong-Jian Liu; Francis S Lee; Xiao-Yuan Li; Francis Bambico; Ronald S Duman; George K Aghajanian
Journal: Biol Psychiatry Date: 2011-10-29 Impact factor: 13.382

2. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.

Authors: Gonzalo Laje; Níall Lally; Daniel Mathews; Nancy Brutsche; Anat Chemerinski; Nirmala Akula; Benjamin Kelmendi; Arthur Simen; Francis J McMahon; Gerard Sanacora; Carlos Zarate
Journal: Biol Psychiatry Date: 2012-07-06 Impact factor: 13.382

Review 3. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.

Authors: Chadi G Abdallah; Gerard Sanacora; Ronald S Duman; John H Krystal
Journal: Annu Rev Med Date: 2014-10-17 Impact factor: 13.739

4. Maximizing exposure therapy: an inhibitory learning approach.

Authors: Michelle G Craske; Michael Treanor; Christopher C Conway; Tomislav Zbozinek; Bram Vervliet
Journal: Behav Res Ther Date: 2014-05-09

5. Clinical predictors of ketamine response in treatment-resistant major depression.

Authors: Mark J Niciu; David A Luckenbaugh; Dawn F Ionescu; Sara Guevara; Rodrigo Machado-Vieira; Erica M Richards; Nancy E Brutsche; Neal M Nolan; Carlos A Zarate
Journal: J Clin Psychiatry Date: 2014-05 Impact factor: 4.384

6. Variation in the BDNF Val66Met polymorphism and response to cognitive-behavior therapy in obsessive-compulsive disorder.

Authors: M A Fullana; P Alonso; M Gratacòs; N Jaurrieta; S Jiménez-Murcia; C Segalàs; E Real; X Estivill; J M Menchón
Journal: Eur Psychiatry Date: 2011-12-06 Impact factor: 5.361

7. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses.

Authors: Erinn S Gideons; Ege T Kavalali; Lisa M Monteggia
Journal: Proc Natl Acad Sci U S A Date: 2014-05-27 Impact factor: 11.205

8. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Authors: W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney
Journal: Arch Gen Psychiatry Date: 1989-11

9. Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.

Authors: Carolyn I Rodriguez; Michael Wheaton; Jordana Zwerling; Shari A Steinman; Danae Sonnenfeld; Hanga Galfalvy; Helen Blair Simpson
Journal: J Clin Psychiatry Date: 2016-03 Impact factor: 4.384